Activity of tigecycline in combination with colistin, meropenem, rifampin, or gentamicin against KPC-producing Enterobacteriaceae in a murine thigh infection model

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 12, 2013, Pages 6028-6033

  Michail, George ^a   Labrou, Maria ^a   Pitiriga, Vassiliki ^b   Manousaka, Styliani ^a   Sakellaridis, Nikolaos ^a   Tsakris, Athanasios ^b   Pournaras, Spyros ^b  

^a UNIVERSITY OF THESSALY   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; CYCLOPHOSPHAMIDE; GENTAMICIN; MEROPENEM; RIFAMPICIN; TIGECYCLINE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEMASE; MINOCYCLINE; THIENAMYCIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ARTICLE; COLONY FORMING UNIT; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENTIATION; ESCHERICHIA COLI; FEMALE; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE; MONOTHERAPY; MOUSE; NEUTROPHIL COUNT; NONHUMAN; PRIORITY JOURNAL; SOFT TISSUE INFECTION; ANALOGS AND DERIVATIVES; ANIMAL; BACTERIAL COUNT; BIOSYNTHESIS; DRUG COMBINATION; DRUG EFFECTS; ENTEROBACTERIACEAE INFECTIONS; ENZYMOLOGY; GROWTH, DEVELOPMENT AND AGING; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; THIGH;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; COLISTIN; COLONY COUNT, MICROBIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENTEROBACTERIACEAE INFECTIONS; ESCHERICHIA COLI; FEMALE; GENTAMICINS; KLEBSIELLA PNEUMONIAE; MICE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; RIFAMPIN; THIENAMYCINS; THIGH;

EID: 84887498769     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00891-13     Document Type: Article

References (30)

1. da Silva RM, Traebert J, Galato D. 2012. Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae: a review of epidemiological and clinical aspects. Expert Opin. Biol. Ther. 12:663-671.
2. Nordmann P, Cuzon G, Naas T. 2009. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect. Dis. 9:228-236.
3. Bratu S, Landman D, Haag R, Recco R, Eramo A, Alam M. 2005. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch. Intern. Med. 165: 1430-1435.
4. Tsakris A, Kristo I, Poulou A, Markou F, Ikonomidis A, Pournaras S. 2008. First occurrence of KPC-2-possessing Klebsiella pneumoniae in a Greek hospital and recommendation for detection with boronic acid disc tests. J. Antimicrob. Chemother. 62:1257-1260.
5. Hirsch EB, Tam VH. 2010. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrugresistant infection. J. Antimicrob. Chemother. 65:1119-1125.
6. Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO. 2009. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase- producing K. pneumoniae. Infect. Control Hosp. Epidemiol. 30: 1180-1185.
7. Pournaras S, Protonotariou E, Voulgari E, Kristo I, Dimitroulia E, Vitti D, Tsalidou M, Maniatis AN, Tsakris A, Sofianou D. 2009. Clonal spread of KPC-2 carbapenemase-producing Klebsiella pneumoniae in Greece. J. Antimicrob. Chemother. 64:348-352.
8. Ertenza JM, Moreillon P. 2009. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int. J. Antimicrob. Agents 34:8.e1-8.e9. doi:10.1016/j.ijantimicag.2008.11.006.
9. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, Polsky B, Adams-Haduch JM, Doi Y. 2012. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob. Agents Chemother. 56:2108-2113.
10. Tessier PR, Nicolau DP. 2013. Tigecycline displays in vivo bactericidal activity against extended spectrum-β-lactamase-producing Klebsiella pneumoniae after 72-hour exposure period. Antimicrob. Agents Chemother. 57:640-642.
11. Petersen PJ, Labthavikul P, Jones CH, Bradford PA. 2006. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J. Antmicrob. Chemother. 57:573-576.
12. Cobo J, Morosini MI, Pintado V, Tato M, Samaranch N, Baquero F, Canton R. 2008. Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 β-lactamase-producing Klebsiella pneumoniae epidemic clone. Diagn. Microbiol. Infect. Dis. 60: 319-322.
13. Pournaras S, Vrioni G, Neou E, Dendrinos J, Dimitroulia E, Poulou A, Tsakris A. 2011. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. Int. J. Antimicrob. Agents 37:244-247.
14. Lee GS, Burgess DS. 2012. Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports. Ann. Clin. Microbiol. Antimicrob. 11:32-41.
15. Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing, 21th informational supplement. M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.
16. Ikonomidis A, Michail G, Vasdeki A, Labrou M, Karavasilis V, Stathopoulos C, Maniatis A, Pournaras S. 2008. In vitro and in vivo evaluations of oxacillin efficiency against mecA-positive oxacillin-susceptible Staphylococcus aureus. Antimicrob. Agents Chemother. 52:3905-3908.
17. Hegde SS, Reyes N, Skinner R, Difuntorum S. 2008. Efficacy of telavancin in a murine model of pneumonia induced by methicillin-susceptible Staphylococcus aureus. J. Antimicrob. Chemother. 61:169-172.
18. Andes D, van Ogtrop ML, Peng J, Craig WA. 2002. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob. Agents Chemother. 46:3484-3489.
19. LaPlante KL, Leonard SN, Andes DR, Craig WA, Rybak MJ. 2008. Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim- sulfamethoxazole, and vancomycin against community associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models. Antimicrob. Agents Chemother. 52:2156-2162.
20. Barthold SW, Hodzic E, Imai DM, Feng S, Yang X, Luft BJ. 2010. Ineffectiveness of tigecycline against persistent Borrelia burgdorferi. Antimicrob. Agents Chemother. 54:643-651.
21. Lenz MA, Franklin GA, Fairweather M, McClintock ML, Jala VR, Peyton JC, Gardner SA, Cheadle WG. 2007. Endogenous IL-10 leads to impaired bacterial clearance and reduced survival in a murine model of chronic peritonitis. Cytokine 40:207-215.
22. Pachón-Ibáñez ME, Docobo-Perez F, Lopez-Rojas R, Domínguez-Herrera J, Jiménez-Mejias ME, García-Curiel A, Pichardo C, Jiménez L, Pachón J. 2010. Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 54:1165-1172.
23. Dudhani RV, Turnidge JD, Nation RL, Li J. 2010. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J. Antimicrob. Chemother. 65:1984-1990.
24. Tam VH, Ledesma KR, Schilling AN, Lim TP, Yuan Z, Ghose R, Lewis RE. 2009. In vivo dynamics of carbapenem-resistant Pseudomonas aeruginosa selection after suboptimal dosing. Diagn. Microbiol. Infect. Dis. 64: 427-433.
25. Morinaga Y, Yanagihara K, Nakamura S, Yamamoto K, Izumikawa K, Seki M, Kakeya H, Yamamoto Y, Yamada Y, Kohno S, Kamihira S. 2008. In vivo efficacy and pharmacokinetics of tomopenem (CS-023), a novel carbapenem, against Pseudomonas aeruginosa in a murine chronic respiratory tract infection model. J. Antimicrob. Chemother. 62:1326-1331.
26. Rishi P, Preet S, Bharrhan S, Verma I. 2011. In vitro and in vivo synergistic effects of cryptdin 2 and ampicillin against Salmonella. Antimicrob. Agents Chemother. 55:4176-4182.
27. Agwuh KN, MacGowan A. 2006. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J. Antimicrob. Chemother. 58:256-265.
28. Montero A, Ariza J, Corbella X, Doménech A, Cabellos C, Ayats J, Tubau F, Borraz C, Gudiol F. 2004. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J. Antimicrob. Chemother. 56:1085-1091.
29. Albur M, Noel A, Bowker K, MacGowan A. 2012. Bactericidal activity of multiple combinations of tigecycline and colistin against NDM-1-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 56:3441-3443.
30. Weisenberg SA, Morgan DJ, Espinal-Witter R, Larone DH. 2009. Clinical outcomes of patients with Klebsiella pneumoniae carbapenemaseproducing K. pneumoniae after treatment with imipenem or meropenem. Diagn. Microbiol. Infect. Dis. 64:233-235.